Healthcare company Labcorp announced Tuesday, Jan. 20 a multi-year plan for a new, purpose-built, high-tech facility for its ...

The company said that the sale of its medical device testing business would allow it to focus on core areas of preclinical drug development and chemical testing.

The move adds Labcorp’s US biocompatibility, analytical testing, and preclinical research services to Namsa’s operations.

The Nature Index tracks primary research articles from 145 natural-science and health-science journals, chosen based on reputation by an independent group of researchers. The Nature Index provides ...

TOLEDO - NAMSA, a medical device testing and regulatory consulting firm, has acquired Labcorp’s (NYSE:LH) Early Development medical device testing business, according to a press release issued ...

The global life sciences and health care company did not explain why it is closing the facility. The post Labcorp is closing ...

Labcorp Holdings Inc. (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today that its Board of Directors has declared a cash dividend of $0.72 per share of ...

Article ‘Count’ and ‘Share’ for Labcorp Drug Development based on listed parameters only. The articles listed below published by authors from Labcorp Drug Development, organized by journal and article ...